Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
Other Sizes |
|
Purity: ≥98%
Tamoxifen Citrate (ICI-46474, NSC-180973; Nolvadex, Novaldex), the citrate salt of ICI-46474, is a selective estrogen receptor modulator (SERM) with potent antitumor activity. It acts by competitively inhibiting estrogen binding in breast tissues. In other tissues like the endometrium, tamoxifen acts as an agonist, and thus is is called a selective estrogen-receptor modulator. Tamoxifen is has been approved for treating hormone receptor-positive breast cancer in pre-menopausal women.
ln Vitro |
Tamoxifen Citrate (ICI 46474) does not influence MDA-MB-231 cells, but it has a significant inhibitory effect on MCF-7 cells (EC50=1.41 μM) and a lessened inhibitory effect on T47D cells (EC50=2.5 μM)[2].
|
||
---|---|---|---|
ln Vivo |
The ability to arbitrarily eliminate gene expression in adult animals in a tissue-specific way is one of the strategy's obvious advantages when using Tamoxifen Citrate-induced knockout. Tamoxifen citrate, 65 mg/kg per day, was intraperitoneally given into 7-week-old TmcsMed1-/- mice to investigate the function of Med1 in the adult heart. The mice were then euthanized at predetermined intervals. time after that. Three days after the Tamoxifen Citrate injection, Med1 expression started to decline (by about 70%), and five days later, Med1 expression in the heart was essentially nonexistent, according to qPCR analysis of RNA. Dilated cardiomyopathy is the result of heart-specific disruption of Med1 (TmcsMed1-/-) in adult mice caused by tamoxifen citrate [3].
|
||
Animal Protocol |
|
||
References |
[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18.
[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [3]. Jia Y, et al. Cardiomyocyte-Specific Ablation of Med1 Subunit of the Mediator Complex Causes Lethal DilatedCardiomyopathy in Mice. PLoS One. 2016 Aug 22;11(8):e0160755. [4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [5]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63 |
Molecular Formula |
C26H29NO.C6H8O7
|
|
---|---|---|
Molecular Weight |
563.64
|
|
CAS # |
54965-24-1
|
|
SMILES |
O(C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H])C1C([H])=C([H])C(=C([H])C=1[H])/C(/C1C([H])=C([H])C([H])=C([H])C=1[H])=C(\C1C([H])=C([H])C([H])=C([H])C=1[H])/C([H])([H])C([H])([H])[H].O([H])C(C(=O)O[H])(C([H])([H])C(=O)O[H])C([H])([H])C(=O)O[H]
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7742 mL | 8.8709 mL | 17.7418 mL | |
5 mM | 0.3548 mL | 1.7742 mL | 3.5484 mL | |
10 mM | 0.1774 mL | 0.8871 mL | 1.7742 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.